Eine multizentrische, einarmige, nicht-interventionelle, prospektive Beobachtungsstudie zur Erfassung der demographischen Merkmale, der Krankheitslast und des Zeitpunktes der Symptomlinderung bei Patienten ab 18 Jahren mit schwerem eosinophilem Asthma, die eine Behandlung mit Benralizumab beginnen.

Inclusion Criteria:

Subject eligible for enrolment in the study and treatment for benralizumab according to the
specific Swiss label must meet all the following criteria:

1. Male or female patients older than 18 years with physician's confirmed diagnosis of
severe, uncontrolled asthma according to ATS/ERS guidelines.

2. Asthma requiring high-dose ICS plus LABA as maintenance treatment.

3. Minimum of 2 exacerbations in the last 12 months.

4. Documented peripheral blood eosinophil count = 300 cells/µL blood.

5. Provision of signed written informed consent form (ICF) indicating that they
understand the purpose of the study and procedures required for participation in the
study.

6. Patients must be able and willing to read and comprehend written instructions, and
comprehend and complete the questionnaires required by the protocol (ACQ-5, PGI-C and
PGI-S).

Exclusion Criteria:

Subjects meeting any of the following criteria will not be eligible to participate in the
study:

1. Documented lung diseases other than asthma, e.g. COPD, and not within reimbursed
label, e.g pregnancy or lactation.

2. Currently enrolled in an interventional clinical study in parallel, except:

- Patients being in parallel documented in a national asthma registry.

- Patients having completed any other clinical trial including those with biologic
treatment.

3. An acute or chronic condition that, in the investigator's opinion, would limit the
patients' ability to complete questionnaires or participate in this study or impact
the interpretations of results.